Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease.

Literature DB >> 29281112

Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease.

Michelle Meyer¹, Eric Huang², Olga Yuzhakov³, Palaniappan Ramanathan¹, Giuseppe Ciaramella³, Alexander Bukreyev^1,4,5,6.

Abstract

Most current Ebola virus (EBOV) vaccine candidates are based on viral vectors, some of which cause side effects or require complex manufacturing. Modified mRNA vaccines are easily produced, safe, and are highly immunogenic. We developed 2 mRNA vaccines based on the EBOV envelope glycoprotein, which differed by the nature of signal peptide for improved glycoprotein post-translational translocation. The mRNAs were formulated with lipid nanoparticles to facilitate delivery. Vaccination of guinea pigs induced EBOV-specific IgG and neutralizing antibody responses and 100% survival after EBOV infection. The efficacy of our mRNA vaccine combined with preclinical safety data supports testing in clinical studies.

Entities: Chemical Disease Species

Keywords: Ebola virus; RNA; antibody response; immunization; vaccine

Mesh：

Substances：

Year: 2018 PMID： 29281112 PMCID： PMC5853918 DOI： 10.1093/infdis/jix592

Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226

15 in total

1. Direct gene transfer into mouse muscle in vivo.

Authors: J A Wolff; R W Malone; P Williams; W Chong; G Acsadi; A Jani; P L Felgner
Journal: Science Date: 1990-03-23 Impact factor: 47.728

2. Modified mRNA Vaccines Protect against Zika Virus Infection.

Authors: Justin M Richner; Sunny Himansu; Kimberly A Dowd; Scott L Butler; Vanessa Salazar; Julie M Fox; Justin G Julander; William W Tang; Sujan Shresta; Theodore C Pierson; Giuseppe Ciaramella; Michael S Diamond
Journal: Cell Date: 2017-02-17 Impact factor: 41.582

3. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.

Authors: Michelle Meyer; Tania Garron; Ndongala M Lubaki; Chad E Mire; Karla A Fenton; Curtis Klages; Gene G Olinger; Thomas W Geisbert; Peter L Collins; Alexander Bukreyev
Journal: J Clin Invest Date: 2015-07-13 Impact factor: 14.808

4. Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

Authors: Teresa Coelho; David Adams; Ana Silva; Pierre Lozeron; Philip N Hawkins; Timothy Mant; Javier Perez; Joseph Chiesa; Steve Warrington; Elizabeth Tranter; Malathy Munisamy; Rick Falzone; Jamie Harrop; Jeffrey Cehelsky; Brian R Bettencourt; Mary Geissler; James S Butler; Alfica Sehgal; Rachel E Meyers; Qingmin Chen; Todd Borland; Renta M Hutabarat; Valerie A Clausen; Rene Alvarez; Kevin Fitzgerald; Christina Gamba-Vitalo; Saraswathy V Nochur; Akshay K Vaishnaw; Dinah W Y Sah; Jared A Gollob; Ole B Suhr
Journal: N Engl J Med Date: 2013-08-29 Impact factor: 91.245

5. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.

Authors: Angela Huttner; Julie-Anne Dayer; Sabine Yerly; Christophe Combescure; Floriane Auderset; Jules Desmeules; Markus Eickmann; Axel Finckh; Ana Rita Goncalves; Jay W Hooper; Gürkan Kaya; Verena Krähling; Steve Kwilas; Barbara Lemaître; Alain Matthey; Peter Silvera; Stephan Becker; Patricia E Fast; Vasee Moorthy; Marie Paule Kieny; Laurent Kaiser; Claire-Anne Siegrist
Journal: Lancet Infect Dis Date: 2015-08-04 Impact factor: 25.071

6. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates.

Authors: Gary Wong; Jason S Richardson; Stéphane Pillet; Ami Patel; Xiangguo Qiu; Judie Alimonti; Jeff Hogan; Yi Zhang; Ayato Takada; Heinz Feldmann; Gary P Kobinger
Journal: Sci Transl Med Date: 2012-10-31 Impact factor: 17.956

7. Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.

Authors: Stephen B Kennedy; Fatorma Bolay; Mark Kieh; Greg Grandits; Moses Badio; Ripley Ballou; Risa Eckes; Mark Feinberg; Dean Follmann; Birgit Grund; Swati Gupta; Lisa Hensley; Elizabeth Higgs; Krisztina Janosko; Melvin Johnson; Francis Kateh; James Logue; Jonathan Marchand; Thomas Monath; Martha Nason; Tolbert Nyenswah; François Roman; Eric Stavale; Julian Wolfson; James D Neaton; H Clifford Lane
Journal: N Engl J Med Date: 2017-10-12 Impact factor: 91.245

8. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose.

Authors: Jasdave S Chahal; Omar F Khan; Christopher L Cooper; Justine S McPartlan; Jonathan K Tsosie; Lucas D Tilley; Saima M Sidik; Sebastian Lourido; Robert Langer; Sina Bavari; Hidde L Ploegh; Daniel G Anderson
Journal: Proc Natl Acad Sci U S A Date: 2016-07-05 Impact factor: 11.205

9. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge.

Authors: Norbert Pardi; Anthony J Secreto; Xiaochuan Shan; Fotini Debonera; Joshua Glover; Yanjie Yi; Hiromi Muramatsu; Houping Ni; Barbara L Mui; Ying K Tam; Farida Shaheen; Ronald G Collman; Katalin Karikó; Gwenn A Danet-Desnoyers; Thomas D Madden; Michael J Hope; Drew Weissman
Journal: Nat Commun Date: 2017-03-02 Impact factor: 14.919

10. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses.

Authors: Kapil Bahl; Joe J Senn; Olga Yuzhakov; Alex Bulychev; Luis A Brito; Kimberly J Hassett; Michael E Laska; Mike Smith; Örn Almarsson; James Thompson; Amilcar Mick Ribeiro; Mike Watson; Tal Zaks; Giuseppe Ciaramella
Journal: Mol Ther Date: 2017-04-27 Impact factor: 12.910

49 in total

1. A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice.

Authors: Alec W Freyn; Jamile Ramos da Silva; Victoria C Rosado; Carly M Bliss; Matthew Pine; Barbara L Mui; Ying K Tam; Thomas D Madden; Luís Carlos de Souza Ferreira; Drew Weissman; Florian Krammer; Lynda Coughlan; Peter Palese; Norbert Pardi; Raffael Nachbagauer
Journal: Mol Ther Date: 2020-04-19 Impact factor: 11.454

Review 2. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Authors: Giulietta Maruggi; Cuiling Zhang; Junwei Li; Jeffrey B Ulmer; Dong Yu
Journal: Mol Ther Date: 2019-02-07 Impact factor: 11.454

3. Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection.

Authors: Amy S Espeseth; Pedro J Cejas; Michael P Citron; Dai Wang; Daniel J DiStefano; Cheryl Callahan; Gregory O' Donnell; Jennifer D Galli; Ryan Swoyer; Sinoeun Touch; Zhiyun Wen; Joseph Antonello; Lan Zhang; Jessica A Flynn; Kara S Cox; Daniel C Freed; Kalpit A Vora; Kapil Bahl; Andrew H Latham; Jeffrey S Smith; Marian E Gindy; Giuseppe Ciaramella; Daria Hazuda; Christine A Shaw; Andrew J Bett
Journal: NPJ Vaccines Date: 2020-02-14 Impact factor: 7.344

4. Attenuated activation of pulmonary immune cells in mRNA-1273-vaccinated hamsters after SARS-CoV-2 infection.

Authors: Michelle Meyer; Yuan Wang; Darin Edwards; Gregory R Smith; Aliza B Rubenstein; Palaniappan Ramanathan; Chad E Mire; Colette Pietzsch; Xi Chen; Yongchao Ge; Wan Sze Cheng; Carole Henry; Angela Woods; LingZhi Ma; Guillaume Be Stewart-Jones; Kevin W Bock; Mahnaz Minai; Bianca M Nagata; Sivakumar Periasamy; Pei-Yong Shi; Barney S Graham; Ian N Moore; Irene Ramos; Olga G Troyanskaya; Elena Zaslavsky; Andrea Carfi; Stuart C Sealfon; Alexander Bukreyev
Journal: J Clin Invest Date: 2021-10-15 Impact factor: 14.808

Review 5. mRNA vaccines: Past, present, future.

Authors: Mia Karam; Georges Daoud
Journal: Asian J Pharm Sci Date: 2022-06-30 Impact factor: 9.273

6. Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide.

Authors: Carly Fleagle Chisholm; Taek Jin Kang; Miao Dong; Kasey Lewis; Madhuri Namekar; Axel T Lehrer; Theodore W Randolph
Journal: Eur J Pharm Biopharm Date: 2019-01-28 Impact factor: 5.571

7. Evaluation of a Single-Dose Nucleoside-Modified Messenger RNA Vaccine Encoding Hendra Virus-Soluble Glycoprotein Against Lethal Nipah virus Challenge in Syrian Hamsters.

Authors: Michael K Lo; Jessica R Spengler; Stephen R Welch; Jessica R Harmon; JoAnn D Coleman-McCray; Florine E M Scholte; Punya Shrivastava-Ranjan; Joel M Montgomery; Stuart T Nichol; Drew Weissman; Christina F Spiropoulou
Journal: J Infect Dis Date: 2020-05-11 Impact factor: 5.226